EPISODE · Jan 3, 2024 · 20 MIN
Targeting a Multitude of CIN in Cancer Cells
from The Bio Report · host Levine Media Group
It’s long been understood that chromosomal instability (CIN) is a characteristic of cancer cells, but it also represents a key difference between cancer cells and healthy cells that can be exploited. Volastra is developing medicines for a wide range of difficult-to-treat cancers that target the vulnerabilities of these cells. We spoke to Charles Hugh-Jones, CEO of Volastra, about chromosomal instability in cancer cells, how the company is developing a pipeline of therapies to exploit this, and its expanding relationships with Big Pharma.
What this episode covers
Charles Hugh-Jones, CEO of Volastra, discusses chromosomal instability in cancer cells, how the company is developing a pipeline of therapies to exploit this, and its expanding relationships with Big Pharma .
NOW PLAYING
Targeting a Multitude of CIN in Cancer Cells
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m